×
For best experience we recommend to activate Javascript in your browser.
ECT2 antibody (AA 166-348)
This anti-ECT2 antibody is a Rabbit Polyclonal antibody detecting ECT2 in WB, IHC, IP and ICC. Suitable for Human.
Quick Overview for ECT2 antibody (AA 166-348) (ABIN7616712)
Target
See all ECT2 Antibodies
ECT2
(Epithelial Cell Transforming Sequence 2 Oncogene (ECT2))
Reactivity
All reactivities for ECT2 antibodies
Human
Host
All hosts for ECT2 antibodies
Rabbit
Clonality
All clonalities for ECT2 antibodies
Polyclonal
Conjugate
All conjugates for ECT2 antibodies
This ECT2 antibody is un-conjugated
Application
All applications for ECT2 antibodies
Western Blotting (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunocytochemistry (ICC)
Product Details anti-ECT2 Antibody
(hide)
Binding Specificity
All epitopes for ECT2 antibodies
AA 166-348
Purpose
Epithelial Cell Transforming Sequence 2 (ECT2) Polyclonal Antibody
Sequence
Leu166~Arg348
Characteristics
The Epithelial Cell Transforming Sequence 2 (ECT2) Polyclonal Antibody (Species: Human) has been validated for the following applications: WB, IHC, ICC, IP.
Purification
Antigen-specific affinity chromatography followed by Protein A affinity chromatography
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Concentration
0.5 mg/mL
Buffer
0.01M PBS, pH 7.4, containing 0.05 % Proclin-300, 50 % glycerol
Preservative
ProClin
Precaution of Use
This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
2°C to 8°C for frequent use, -20°C for 12 months. Avoid repeated freeze/thaw cycles.
Expiry Date
12 months
Target Details for ECT2
(hide)
Target
ECT2
(Epithelial Cell Transforming Sequence 2 Oncogene (ECT2))
Alternative Name
ECT2
Gene ID
1894
UniProt
Q9H8V3
Pathways
Neurotrophin Signaling Pathway , Cell-Cell Junction Organization
Recently viewed
(hide)
Chat with us , powered by LiveChat